Avalo Therapeutics (AVTX) Q3 2024 Earnings
AVTX·Reported November 7, 2024·Before market open
Avalo Therapeutics reported Q3 2024 revenue of $249.0K. Diluted EPS came in at $-2.83, missed the $-1.19 consensus by $1.64.
Revenue
$249.0K
Diluted EPS
$-2.83missed by $1.64
Consensus: $-1.19
Financial Snapshot
Trailing eight quarters through Q3 2024
Q3 2024 Earnings FAQ
Common questions about Avalo Therapeutics's Q3 2024 earnings report.
Avalo Therapeutics (AVTX) reported Q3 2024 earnings on November 7, 2024 before market open.
Avalo Therapeutics reported revenue of $249.0K and diluted EPS of $-2.83 for Q3 2024.
EPS missed the consensus estimate of $-1.19 by $1.64.
You can read the 10-Q periodic report (0001628280-24-045965) directly on SEC EDGAR. The filing index links above go to sec.gov.